TipHub

₹0.53

▼ -0.01 -1.85%

29 Jul 2026

BSE Listed

GSM · GSM 0
What does GSM · GSM 0 mean?
BSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).Exchange notice · 2026-06-25

Shree Ganesh Biotech India Ltd. (539470)

Volume: 4,64,931Avg Vol 1W: 5,22,413Avg Vol 1M: 5,64,07552W Range:₹0.52₹0.82
BSE www.shreeganeshbiotech.com AI Report
Key Ratios
Checked just now
Market Cap₹21 Cr
Current Price₹0.53
Previous Close₹0.54
High / Low (52w)₹0.82 / ₹0.52
Volume4,64,931
Avg Vol (1W)5,22,413
Avg Vol (1M)5,64,075
Stock P/E53
Book Value₹1.6
Dividend Yield0%
ROE59.34%
ROA79.94%
Revenue (TTM)—
Revenue Growth—
Profit Margin10.26%
Total Debt—
Shares Outstanding40 Cr
Face Value—
EPS (TTM)₹0.01
P/B0.33
Debt / Equity0
50 DMA₹0.58
200 DMA₹0.63
Day change-1.85%
SurveillanceGSM · GSM 0
Price Chart
₹0.53▼ 32.91% · 1Y
₹1₹129.7L
2025-07-29
2026-07-29

20-day avg volume: 5.2L shares

Pros
  • Healthy return on equity of 59.3%.
  • Company is almost debt-free.
  • Revenue grew 14% YoY.
  • Stock trades below its book value.
Cons
  • Stock trades at a high P/E of 53.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹4 Cr₹2 Cr₹14 Cr₹3 Cr₹1 Cr₹1 Cr₹1 Cr₹2 Cr
EBITDA₹0 Cr₹0 Cr₹1 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹1 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹8 Cr₹6 Cr₹2 Cr₹17 Cr₹73 Cr₹63 Cr₹21 Cr₹24 Cr
EBITDA₹4 Cr₹2 Cr₹0 Cr₹1 Cr₹3 Cr₹3 Cr₹1 Cr₹0 Cr
Net Profit₹4 Cr₹2 Cr₹0 Cr₹0 Cr₹3 Cr₹2 Cr₹1 Cr₹0 Cr
EPS19.120.90.120.020.130.050.020.01
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹26 Cr₹64 Cr₹65 Cr₹75 Cr₹94 Cr₹80 Cr₹74 Cr₹63 Cr
Total Liabilities₹3 Cr₹7 Cr₹7 Cr₹17 Cr₹33 Cr₹17 Cr₹11 Cr₹0 Cr
Equity₹23 Cr₹57 Cr₹57 Cr₹58 Cr₹60 Cr₹62 Cr₹63 Cr₹63 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹2 Cr₹5 Cr₹11 Cr₹10 Cr₹-10 Cr
Investing₹-2 Cr₹-3 Cr₹-10 Cr₹-10 Cr₹10 Cr
Financing₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Free Cash Flow₹2 Cr₹5 Cr₹11 Cr₹10 Cr₹-10 Cr
Shareholding
Promoter 0% Institutions 1.42% Public 98.58%
Efficiency & Working Capital
ROCE0.8%
Interest Coverage0
Dividend Payout—
Debtor Days0 d
Inventory Days46 d
Payable Days0 d
Cash Conversion Cycle46 d
Working Capital Days46 d
Shareholding Details

As of 2026-06-30

Promoter0%
FII1.4%
DII0%
Institutions1.4%
Public98.6%
Promoter Pledge—
No. of Shareholders1,81,722
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters0%0%0%0%0%0%0%0%0%0%0%0%
FIIs2.2%2.2%1.4%1.4%1.4%1.4%1.4%1.4%1.4%1.4%1.4%1.4%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public97.8%97.8%98.6%98.6%98.6%98.6%98.6%98.6%98.6%98.6%98.6%98.6%
Promoter Pledge————————————
No. of Shareholders78,0961,39,8801,76,7221,81,1981,85,3351,92,0401,95,4351,92,2351,89,3751,86,1481,83,6581,81,722
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
New Era Fund LimitedPublic Shareholding1.4%56,64,940
Board of Directors
NameDesignationYear
Aman PatelChairman / Executive Director / WTD2025
Kishan Nityanand NaiduExecutive Director & CFO2025
SOMBIR SINGHIndependent Non Exe. Director2025
Amrutaben SolankiIndependent Non Exe. Director2025
Nimeshkumar ParmarIndependent Non Exe. Director2025
Harshadkumar RathodIndependent Non Exe. Director2025
Namita AcharyaCompany Sec. & Compli. Officer2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹1404040
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-04Board Meetings—
Substantial Acquisitions (SAST)

5 disclosure(s)

Market25/09/2023 - 17/10/2023 · 1,99,00,000
Market12/09/2023 - 16/10/2023 · 2,61,00,000
Off Market11/09/2023 - 13/09/2023 · 3,23,00,000
Market08/09/2023 · 1,95,00,000
Market06/09/2023 · 1,95,50,000
Company Information
Incorporated1982
ChairmanAman Patel
AuditorBipin & co
Investor Email[email protected]
🌐 www.shreeganeshbiotech.com ↗

📍 6 Flr Premises-602 Mahavir Apt, 2 Aushutosh Mukherjee Road, Kolkata, West Bengal, 700020

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Interglobe AviationIGC Industries LimitedSH Kelkar & CompanyAryavan Enterprise LimitedTyphoon Financial Services Ltd.Panorama Studios International Ltd.GTV Engineering LimitedGeetanjali Credit and Capital Ltd.Tirupati Fin-Lease Ltd.Garbi Finvest LimitedSmart Finsec LimitedRajkot Investment Trust LimitedAll “53” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search